{"id":"W2559562829","doi":"10.1016/s1470-2045(16)30558-7","title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":254,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Polycythaemia; Ruxolitinib; Internal medicine; Polycythemia vera; Clinical endpoint; Myeloproliferative neoplasm; Randomized controlled trial; Pediatrics; Myelofibrosis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00231227,0.001591887,0.00323956,0.000398579,0.0003595212,0.001397597,0.0008866294,0.002120714,0.005537181],"category_scores_gemma":[0.001478384,0.0006451756,0.002378684,0.0003791698,0.001035814,0.001379175,0.0003606937,0.003584177,0.001157474],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006711083,"about_ca_system_score_gemma":0.0006846146,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007998637,"about_ca_topic_score_gemma":0.001586507,"domain_scores_codex":[0.9993255,0.0003636173,0.00003194164,0.00009116262,0.00004636886,0.0001414054],"domain_scores_gemma":[0.9991006,0.0003124699,0.000176302,0.0000872071,0.00004961841,0.0002737891],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9488465,0.008582726,0.0008555109,0.0009379776,0.00122775,0.0001142161,0.00009142387,0.0006447326,0.005223325,0.0001718263,0.001486658,0.03181732],"study_design_scores_gemma":[0.9393095,0.05722125,0.001757524,0.00003349086,0.0002751251,0.00007460968,0.00002329921,0.0003252603,0.0002661916,0.0001213,0.000574246,0.00001827805],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9860633,0.006751657,0.0007612024,0.0008693578,0.0003916252,0.001957303,0.001170512,0.0001499274,0.001885058],"genre_scores_gemma":[0.9870705,0.003853459,0.001195442,0.001403891,0.000411806,0.00181374,0.001398129,0.00003680464,0.002816307],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005537181,"threshold_uncertainty_score":0.01852369,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1614760596358667,"score_gpt":0.4526537947164275,"score_spread":0.2911777350805609,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}